Document is current
Any future updates will be listed below
-
Authors
Cacace, Elisabetta http://orcid.org/0000-0001-8239-0353
Kim, Vladislav http://orcid.org/0000-0001-5061-7285
Varik, Vallo http://orcid.org/0000-0001-6900-6986
Knopp, Michael http://orcid.org/0000-0002-8218-3263
Tietgen, Manuela http://orcid.org/0000-0001-5117-4340
Brauer-Nikonow, Amber http://orcid.org/0000-0003-4146-2458
Inecik, Kemal http://orcid.org/0000-0001-7379-9093
Mateus, André
Milanese, Alessio http://orcid.org/0000-0002-7050-2239
Mårli, Marita Torrissen http://orcid.org/0009-0001-1535-7032
Mitosch, Karin
Selkrig, Joel
Brochado, Ana Rita http://orcid.org/0000-0003-1703-383X
Kuipers, Oscar P. http://orcid.org/0000-0001-5596-7735
Kjos, Morten http://orcid.org/0000-0003-4448-9082
Zeller, Georg
Savitski, Mikhail M. http://orcid.org/0000-0003-2011-9247
Göttig, Stephan http://orcid.org/0000-0001-6896-5309
Huber, Wolfgang
Typas, Athanasios http://orcid.org/0000-0002-0797-9018
-
Funding
Funding for this research was provided by:
European Molecular Biology Laboratory (Internal budget)
Joint Programming Initiative on Antimicrobial Resistance (Disrupt, Combinatorials, Disrupt)
Goethe-Universität Frankfurt am Main
Norges Miljø- og Biovitenskapelige Universitet
- License Information
-
More Information
Article History
Received: 23 December 2022
Accepted: 30 August 2023
First Online: 28 September 2023
Competing interests
: EMBL has filed a patent application (European patent application number EP22207154.0) on drug combinations identified in this study (‘Novel combinations of antibiotics and non-antibiotic drugs effective in vivo against Gram-positive bacteria, in particular methicillin-resistant <i>S. aureus</i> (MRSA)’). E.C., S.G. and A.T. are listed as inventors. The remaining authors declare no competing interests.
